NHD Global
Longevity & Bioregulators · Source-reviewed dossier
Source-Reviewed Research Dossier
Thymosin alpha-1 (thymalfasin) is a 28-amino-acid peptide studied as an immune modulator in infection, oncology and immune-response settings. Outcomes remain indication-, regimen- and product-specific and do not establish general immune enhancement.
Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; the current product specification and lot COA control.
Product identity
Literature reference parameters
Identity safeguard Reference identifiers above describe the literature compound record. The supplied form, formula, molecular weight, purity and storage conditions must be verified against the product-specific specification and lot COA.
A target-to-pathway view grounded in the linked research records.
Reported research findings
Reported outcomes are paired with their experimental model and evidence boundary.
A 2020 review summarized thymosin alpha-1 biology and reported uses across immune-compromised and infectious-disease settings.
The review does not support unrestricted use or interchangeability of materials.
Read the primary studyA 2018 review assessed thymosin alpha-1 as an adjunct in sepsis and discussed the limits of the available clinical literature.
Adjunctive sepsis evidence is not a general immune-health claim.
Read the primary studyCatalog options
Pack-level catalog data; lot-level controls remain document-specific.
Single-component peptide · 5 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Single-component peptide · 10 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Document availability is stated honestly and can vary by catalog variant or lot.
Analytical interpretation
Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.
Open the Quality & Documentation HubHPLC area ≠ assayA dominant peak does not establish target mass fraction.
Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.
Counterions affect contentWater, salt form and solvents change the as-is composition.
Storage needs a data basisShipping practice is not the same as stability evidence.
Evidence map
Published studies and regulatory records, not customer testimonials or usage guidance.
The review does not support unrestricted use or interchangeability of materials.
View primary recordAdjunctive sepsis evidence is not a general immune-health claim.
View primary recordThird-party publications selected for direct relevance.
Dominari A, et al. World J Virol. 2020. PMID 33362999.
Clinical review. 2018. PMID 30063866.
Concise answers for researchers comparing identity, evidence and catalog variants.
Thymosin alpha-1 (thymalfasin) is a 28-amino-acid peptide studied as an immune modulator in infection, oncology and immune-response settings. Outcomes remain indication-, regimen- and product-specific and do not establish general immune enhancement.
Reviews cover both laboratory and clinical studies, with heterogeneous indications and study quality.
No. The cited records describe their own intervention, formulation, model and controls. They do not verify the identity, purity, sterility, safety or efficacy of a catalog lot.
A lot-specific COA, product specification sheet and analytical method summary can be requested where applicable.
Store at -20 °C, protected from light and moisture. After reconstitution, aliquot and avoid repeated freeze-thaw cycles. Confirm the applicable storage statement on the product-specific specification and lot documentation.
Knowledge center
Owned educational content connected to this family.
The 2025 TESTS trial is more informative than earlier small sepsis reports: 1,106 adults were randomized across 22 centers, and thymosin alpha-1 did not…
Updated September 1, 2026
Thymalfasin is synthetic thymosin alpha-1: a defined 28-amino-acid peptide with an N-terminal acetyl group. Sequence and acetylation are part of identity, not optional catalog…
Updated September 1, 2026Knowledge tools
Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.
Claims were checked against the linked primary publication, regulatory label or authoritative compound record. Published findings stay attached to their study model, formulation and route. Catalog identity and lot quality remain controlled by the applicable specification and lot-specific documents.
Technical procurement
Selected: TA5 · 5 mg × 10 vials
Tell us what you need. Your enquiry will be routed to the appropriate contact for catalog numbers, availability and quotation details.
